vs
Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
ECB Bancorp, Inc. is the larger business by last-quarter revenue ($9.5M vs $6.5M, roughly 1.5× Prelude Therapeutics Inc). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs -303.5%, a 330.8% gap on every dollar of revenue. On growth, Prelude Therapeutics Inc posted the faster year-over-year revenue change (116.7% vs 33.8%).
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
ECBK vs PRLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $6.5M |
| Net Profit | $2.6M | $-19.7M |
| Gross Margin | — | — |
| Operating Margin | 36.7% | -314.1% |
| Net Margin | 27.3% | -303.5% |
| Revenue YoY | 33.8% | 116.7% |
| Net Profit YoY | 79.5% | 38.9% |
| EPS (diluted) | $0.32 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.5M | — | ||
| Q3 25 | $8.8M | $6.5M | ||
| Q2 25 | $8.0M | — | ||
| Q1 25 | $6.9M | — | ||
| Q4 24 | $7.1M | — | ||
| Q3 24 | $6.6M | $3.0M | ||
| Q2 24 | $6.3M | — | ||
| Q1 24 | $6.2M | — |
| Q4 25 | $2.6M | — | ||
| Q3 25 | $2.4M | $-19.7M | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.1M | $-32.3M | ||
| Q2 24 | $791.0K | — | ||
| Q1 24 | $621.0K | — |
| Q4 25 | 36.7% | — | ||
| Q3 25 | 37.0% | -314.1% | ||
| Q2 25 | 23.9% | — | ||
| Q1 25 | 24.9% | — | ||
| Q4 24 | 27.3% | — | ||
| Q3 24 | 23.3% | -1145.9% | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 13.4% | — |
| Q4 25 | 27.3% | — | ||
| Q3 25 | 27.7% | -303.5% | ||
| Q2 25 | 18.0% | — | ||
| Q1 25 | 18.7% | — | ||
| Q4 24 | 20.3% | — | ||
| Q3 24 | 17.2% | -1075.7% | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $0.29 | $-0.26 | ||
| Q2 25 | $0.17 | — | ||
| Q1 25 | $0.16 | — | ||
| Q4 24 | $0.18 | — | ||
| Q3 24 | $0.14 | $-0.43 | ||
| Q2 24 | $0.09 | — | ||
| Q1 24 | $0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.8M | $55.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.9M | $58.5M |
| Total Assets | $1.6B | $94.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.8M | — | ||
| Q3 25 | $201.9M | $55.0M | ||
| Q2 25 | $191.0M | — | ||
| Q1 25 | $143.7M | — | ||
| Q4 24 | $309.4M | — | ||
| Q3 24 | $114.8M | $153.6M | ||
| Q2 24 | $108.7M | — | ||
| Q1 24 | $109.8M | — |
| Q4 25 | $171.9M | — | ||
| Q3 25 | $169.3M | $58.5M | ||
| Q2 25 | $168.3M | — | ||
| Q1 25 | $168.6M | — | ||
| Q4 24 | $168.3M | — | ||
| Q3 24 | $166.0M | $156.4M | ||
| Q2 24 | $166.5M | — | ||
| Q1 24 | $165.8M | — |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | $94.8M | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | $197.2M | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-19.1M |
| Free Cash FlowOCF − Capex | $9.0M | — |
| FCF MarginFCF / Revenue | 94.7% | — |
| Capex IntensityCapex / Revenue | 2.2% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | — | ||
| Q3 25 | $4.0M | $-19.1M | ||
| Q2 25 | $1.9M | — | ||
| Q1 25 | $-631.0K | — | ||
| Q4 24 | $6.2M | — | ||
| Q3 24 | $861.0K | $-27.3M | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $-429.0K | — |
| Q4 25 | $9.0M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-649.0K | — | ||
| Q4 24 | $6.2M | — | ||
| Q3 24 | — | $-27.4M | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $-449.0K | — |
| Q4 25 | 94.7% | — | ||
| Q3 25 | 44.9% | — | ||
| Q2 25 | 23.0% | — | ||
| Q1 25 | -9.4% | — | ||
| Q4 24 | 86.8% | — | ||
| Q3 24 | — | -912.0% | ||
| Q2 24 | 21.4% | — | ||
| Q1 24 | -7.2% | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 0.8% | 0.0% | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.0% | 2.1% | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 3.55× | — | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 4.31× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | -0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
